Skip to main content

Table 3 Designated and estimated prevalence of HPV16 by Linear Array (LA)-only and sequential testing strategies in the United States and Latin America

From: Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation

Genotyping assay performance Time Designated composite prevalence (SD) LA only Sequential testing
Composite prevalence estimate (SD) Estimate-to-true ratio Composite prevalence estimate (SD) Estimate-to-true ratio
United States
Sen = 1.00
Spe = 1.00 		Baseline 0.047 (0.003) 0.047 (0.003) 1.000 0.009 (0.002) 0.191
Reduced 0.023 (0.002) 0.023 (0.002) 1.000 0.004 (0.001) 0.173
% Reduction 51.1 51.1   50  
Sen = 0.95
Spe = 0.95 		Baseline 0.047 (0.003) 0.092 (0.004) 1.958 0.028 (0.003) 0.596
Reduced 0.023 (0.002) 0.071 (0.004) 3.087 0.021 (0.002) 0.913
% Reduction 51.1 22.8   0.7  
Sen = 0.95
Spe = 0.90 		Baseline 0.047 (0.003) 0.140 (0.006) 2.979 0.052 (0.004) 1.106
Reduced 0.023 (0.002) 0.120 (0.005) 5.217 0.044 (0.003) 1.913
% Reduction 51.1 14.3   15.4  
Sen = 0.90
Spe = 0.90 		Baseline 0.047 (0.003) 0.138 (0.005) 2.936 0.051 (0.003) 1.085
Reduced 0.023 (0.002) 0.119 (0.005) 5.174 0.044 (0.003) 1.913
% Reduction 51.1 13.8   13.7  
Sen = 0.90
Spe = 0.85 		Baseline 0.047 (0.003) 0.185 (0.006) 3.936 0.075 (0.004) 1.596
Reduced 0.023 (0.002) 0.167 (0.007) 7.261 0.068 (0.004) 2.957
% Reduction 51.1 9.7   9.3  
Sen = 0.85
Spe = 0.85 		Baseline 0.047 (0.003) 0.183 (0.006) 3.894 0.074 (0.004) 1.574
Reduced 0.023 (0.002) 0.166 (0.006) 7.217 0.068 (0.004) 2.957
% Reduction 51.1 9.3   8.1  
Sen = 0.80
Spe = 0.80 		Baseline 0.047 (0.003) 0.228 (0.006) 4.851 0.097 (0.005) 2.064
Reduced 0.024 (0.002) 0.214 (0.006) 8.917 0.091 (0.005) 3.792
% Reduction 51.1 6.1   6.2  
Latin America
Sen = 1.00
Spe = 1.00 		Baseline 0.033 (0.003) 0.033 (0.003) 1.000 0.004 (0.001) 0.125
Reduced 0.016 (0.002) 0.016 (0.002) 1.000 0.002 (0.001) 0.125
% Reduction 51.5 51.5   50  
Sen = 0.95
Spe = 0.95 		Baseline 0.033 (0.003) 0.080 (0.004) 2.424 0.022 (0.002) 0.667
Reduced 0.016 (0.002) 0.065 (0.004) 4.063 0.017 (0.002) 1.063
% Reduction 51.5 18.7   22.7  
Sen = 0.95
Spe = 0.90 		Baseline 0.033 (0.003) 0.128 (0.005) 3.879 0.046 (0.003) 1.394
Reduced 0.016 (0.002) 0.114 (0.005) 7.125 0.040 (0.003) 2.500
% Reduction 51.5 10.9   13.0  
Sen = 0.90
Spe = 0.90 		Baseline 0.033 (0.003) 0.126 (0.005) 3.818 0.045 (0.003) 1.364
Reduced 0.016 (0.002) 0.113 (0.005) 7.063 0.040 (0.003) 2.500
% Reduction 51.5 10.3   11.1  
Sen = 0.90
Spe = 0.85 		Baseline 0.033 (0.003) 0.175 (0.006) 5.303 0.070 (0.004) 2.121
Reduced 0.016 (0.002) 0.162 (0.006) 10.125 0.065 (0.004) 4.063
% Reduction 51.5 7.4   7.1  
Sen = 0.85
Spe = 0.85 		Baseline 0.033 (0.003) 0.173 (0.006) 5.242 0.069 (0.004) 2.091
Reduced 0.016 (0.002) 0.161 (0.005) 10.062 0.064 (0.004) 4.000
% Reduction 51.5 6.9   7.2  
Sen = 0.80
Spe = 0.80 		Baseline 0.033 (0.003) 0.219 (0.006) 6.636 0.093 (0.005) 2.818
Reduced 0.016 (0.002) 0.209 (0.006) 13.064 0.089 (0.004) 5.563
% Reduction 51.5 4.5   4.3  
  1. Type-specific prevalence at baseline, in the United States: HPV16 = 0.047; in Latin America: HPV16 = 0.033
  2. Reduced: HPV16 is reduced by 50 %
  3. Abbreviations: SD standard deviation, Sen sensitivity, Spe specificity
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us